Sofetabart

Sofetabart (LY-4170156 Antibody) is a humanized IgG1 antibody that specifically targets folate receptor α ( FRα ). Sofetabart can be used to synthesize the antibody-drug conjugate ( ADC ) Sofetabart mipitecan. Sofetabart is applicable to research related to advanced ovarian cancer, platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, as well as platinum-sensitive ovarian cancer ^{[1] [2] [3] [4]}.

In Vitro, Sofetabart (LY-4170156 Antibody) serves as an FRα-targeting antibody for synthesizing the sofetabart mipitecan antibody-drug conjugate (ADC)^[1][2][3][4].

References:
[1]. O'Malley D, et al. Update from the phase I study of sofetabart mipitecan (Sofe-M), an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) in advanced ovarian cancer (OC) [abstract]. ESMO Open. 2026;11(Suppl 6):108188.
[2]. Coyle L. Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials. Bioconjugate Insights. 2026;1(1):49‑66.
[3]. Moore KN, et al. Antibody-drug conjugates in gynaecological cancers: opportunities and challenges. Nature reviews. Clinical oncology. 2026 Jun 17.
[4]. Ray‑Coquard IL, et al. FRAmework‑01: A two‑part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum‑resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum‑based chemotherapy plus bevacizumab in platinum‑sensitive ovarian cancer (PSOC). J Clin Oncol. 2026;44(16_suppl):TPS5644.